Ratings by Oppenheimer (Kostas Biliouris)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/29/2026 | Nurix | NRIX | Maintain | Outperform (Outperform) |
|
Details | ||
| 5/4/2026 | Design Therapeutics Inc | DSGN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/7/2026 | Evommune Inc | EVMN | New Coverage | Outperform (N/A) |
24.58 (12.10) |
-50.77% | Details | |
| 3/12/2026 | Prime Medicine | PRME | New Coverage | Outperform (N/A) |
3.83 (3.52) |
-8.09% | Details | |
| 1/7/2026 | Alnylam Pharmaceuticals | ALNY | New Coverage | Perform (N/A) |
406.40 (288.06) |
-29.12% | Details | |
| 1/7/2026 | Design Therapeutics Inc | DSGN | New Coverage | Outperform (N/A) |
8.82 (13.86) |
57.14% | Details | |
| 12/10/2025 | Centessa Pharmaceuticals | CNTA | New Coverage | Outperform (N/A) |
28.60 (40.50) |
41.61% | Details |
